Peptide Research Database
A curated collection of peer-reviewed scientific studies and research articles on peptides. Every citation links directly to PubMed or the publishing journal.
Research Articles
In-depth reviews of peptide research, written by our research team with full scientific citations.
The Science Behind BPC-157: A Complete Research Review
An in-depth analysis of published research on BPC-157, covering mechanisms of action, tissue healing pathways, and clinical evidence for this gastric pentadecapeptide.
Semaglutide for Weight Loss: Clinical Trial Results
Comprehensive review of the STEP clinical trial program for semaglutide 2.4mg, including weight loss outcomes, safety data, and long-term efficacy results.
TB-500 vs BPC-157: Comparing Recovery Peptides
Side-by-side comparison of TB-500 (thymosin beta-4) and BPC-157 based on published research, covering mechanisms, efficacy, and how they complement each other.
How Tirzepatide Works: Mechanism of Action Explained
Detailed explanation of tirzepatide's dual GIP/GLP-1 receptor agonism, its pharmacology, and results from the SURPASS and SURMOUNT clinical trials.
Ipamorelin and CJC-1295: Growth Hormone Secretagogue Stack
Research review of the ipamorelin and CJC-1295 combination, covering their individual mechanisms, synergistic effects on GH secretion, and published clinical data.
Peptide Reconstitution: The Chemistry Behind Proper Mixing
The pharmaceutical science behind peptide reconstitution, including stability factors, bacteriostatic water chemistry, and evidence-based best practices for handling.
Melanotan II: Research Findings and Safety Profile
Balanced review of melanotan II research including melanocortin receptor pharmacology, pigmentation studies, and documented safety concerns from clinical literature.
NAD+ Peptide Therapy: What the Research Shows
Evidence-based review of NAD+ precursor supplementation including NMN clinical trials, mechanisms of age-related NAD+ decline, and current research on anti-aging effects.
GHK-Cu for Skin and Hair: Scientific Evidence
Review of published research on the copper tripeptide GHK-Cu covering wound healing, skin regeneration, hair growth stimulation, and gene expression modulation.
The Future of GLP-1 Receptor Agonists in Metabolic Research
Forward-looking review of GLP-1 receptor agonist research including next-generation multi-agonists, emerging indications beyond obesity, and the evolution from single to triple receptor targeting.
Study Database
Search and filter peer-reviewed studies from PubMed and major scientific journals.
Showing 41 of 41 studies
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH
Demonstrated that BPC-157 promotes tendon healing through multiple mechanisms including tendon outgrowth from explants, increased cell survival under stress, and enhanced migration of tendon fibroblasts mediated by activation of the FAK-paxillin pathway.
View on PubMedPentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
Chang CH, Tsai WC, Hsu YH, Pang JH
Found that BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts in a dose- and time-dependent manner at both mRNA and protein levels, suggesting a novel mechanism for its tendon healing properties.
View on PubMedGastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P
Comprehensive review of BPC-157 in musculoskeletal healing, demonstrating accelerated recovery of muscle, tendon, ligament, and bone tissues in multiple animal models with effects on angiogenesis, collagen formation, and growth factor modulation.
View on PubMedModulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing
Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P
Showed that BPC-157 significantly modulates angiogenesis during muscle and tendon healing, promoting formation of new blood vessels and accelerating the repair process in injured tissues through VEGF pathway activation.
View on PubMedAchilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation
Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P
Demonstrated that BPC-157 promotes tendon-to-bone healing in rat Achilles detachment models and opposes the negative effects of corticosteroids on the healing process, maintaining tissue integrity and functional recovery.
View on PubMedThymosin beta4 accelerates wound healing
Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK
Landmark study demonstrating thymosin beta-4 increases reepithelialization by 42% over controls at 4 days and up to 61% at 7 days post-wounding, with increased collagen deposition and angiogenesis in treated wounds.
View on PubMedThe regenerative peptide thymosin beta4 accelerates the rate of dermal healing in preclinical animal models and in patients
Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL
Showed that thymosin beta-4 accelerated dermal healing in multiple animal models including diabetic mice and aged mice. In two phase 2 clinical trials of stasis and pressure ulcers, healing was accelerated by almost a month in responding patients.
View on PubMedThymosin beta4 promotes angiogenesis, wound healing, and hair follicle development
Philp D, Nguyen M, Bhatt R, Goldstein AL, Kleinman HK
Demonstrated that thymosin beta-4 promotes angiogenesis, accelerates wound healing, and stimulates hair follicle development. The peptide was shown to increase blood vessel formation and activate stem cell migration to injury sites.
View on PubMedThymosin beta4 enhances the healing of medial collateral ligament injury in rat
Xu T, Zhang R, Dong M, Zhang T, Li J, Ge Y, Liu Y
Showed that thymosin beta-4 significantly enhanced medial collateral ligament healing in rats, improving tissue structure and biomechanical properties compared to untreated controls.
View on PubMedThymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein AL, Hannappel E, Sosne G, Kleinman HK
Comprehensive review of thymosin beta-4 covering its role in cell migration, angiogenesis, and tissue repair. Discusses clinical applications including wound healing, corneal repair, and cardiac protection with favorable safety profiles.
View on PubMedTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey WT, Batterham RL, Bhatt DL, et al.
Two-year STEP 5 trial showing 77.1% of participants on semaglutide 2.4mg achieved at least 5% weight loss at week 104 versus 34.4% with placebo, demonstrating sustained long-term efficacy for weight management.
View on PubMedSemaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Kushner RF, Calanna S, Davies M, et al.
Overview of the STEP trial program showing semaglutide 2.4mg achieved mean weight loss of 14.9-17.4% at 68 weeks, with 69-79% of participants achieving at least 10% weight loss and 32-40% achieving at least 20% weight loss.
View on PubMedEffect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
Wadden TA, Bailey TS, Billings LK, et al.
STEP 3 trial demonstrated that semaglutide combined with intensive behavioral therapy resulted in significantly greater weight loss than placebo plus behavioral therapy, with a mean body weight change of -16.0% versus -5.7%.
View on PubMedEffect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Rubino D, Abrahamsson N, Davies M, et al.
STEP 4 withdrawal trial showed that continued semaglutide treatment maintained weight loss while those switched to placebo regained weight, confirming the need for ongoing treatment to sustain weight loss benefits.
View on PubMedEffect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Rubino DM, Greenway FL, Khalid U, et al.
Head-to-head comparison showing weekly semaglutide 2.4mg produced significantly greater weight loss (-15.8%) than daily liraglutide 3.0mg (-6.4%) at 68 weeks, establishing semaglutide as the more effective GLP-1 RA for weight management.
View on PubMedTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al.
Phase 2 trial of retatrutide in adults with obesity showed the 12mg dose achieved -24.2% mean body weight change at 48 weeks versus -2.1% with placebo, representing the largest weight reduction reported for any anti-obesity medication at the time.
View on PubMedContinued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Aronne LJ, Sattar N, Horn DB, et al.
SURMOUNT-4 showed continued tirzepatide treatment maintained weight loss while switching to placebo led to significant weight regain, confirming sustained treatment is necessary for long-term weight management with tirzepatide.
View on PubMedRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Rosenstock J, Frias JP, Jastreboff AM, et al.
Phase 2 trial in type 2 diabetes showed retatrutide reduced HbA1c by up to 2.2% and body weight by up to 16.9% at 36 weeks, with 82% of participants in the highest dose group achieving HbA1c of 6.5% or less.
View on PubMedEfficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Syed YY
Comprehensive review of tirzepatide showing 16.0-22.5% weight reduction across SURMOUNT trials in adults without diabetes, with the dual GIP/GLP-1 mechanism providing superior efficacy compared to selective GLP-1 RAs alone.
View on PubMedProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhaumick B
Demonstrated that a single injection of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 or more days and IGF-I concentrations by 1.5- to 3-fold for 9-11 days in healthy adults.
View on PubMedPulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA
Showed that CJC-1295 increases trough and mean GH secretion while preserving the natural pulsatile pattern of GH release, indicating physiological GH stimulation rather than non-physiological continuous elevation.
View on PubMedIpamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH
Established ipamorelin as the first selective growth hormone secretagogue that releases GH with potency and efficacy comparable to GHRP-6 but without affecting ACTH, cortisol, prolactin, or FSH levels even at doses 200-fold above the ED50 for GH release.
View on PubMedIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
Andersen NB, Malmlof K, Johansen PB, Andreassen TT, Gregersen G, Oxlund H
Demonstrated that ipamorelin induces longitudinal bone growth in rats in a dose-dependent manner, confirming its biological activity as a growth hormone secretagogue with potential applications in growth-related conditions.
View on PubMedActivation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Sackmann-Sala L, Ding J, Frohman LA, Bhargava R
Showed that CJC-1295-mediated GH/IGF-1 axis activation produces measurable changes in serum protein profiles in healthy adults, providing biomarker evidence for the biological effects of sustained GH stimulation.
View on PubMedGHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A
Comprehensive study showing GHK-Cu modulates multiple cellular pathways involved in skin regeneration including collagen synthesis, anti-inflammatory signaling, and antioxidant enzyme production, with plasma levels declining from 200 ng/mL at age 20 to 80 ng/mL by age 60.
View on PubMedRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Vasquez-Soltero JM, Margolina A
Gene expression analysis revealed GHK-Cu resets the activity of 4,190 human genes to a healthier state, upregulating genes involved in tissue remodeling and wound repair while suppressing genes associated with inflammation and tissue destruction.
View on PubMedThe human tri-peptide GHK and tissue remodeling
Pickart L
Established GHK as a key regulator of tissue remodeling that stimulates both synthesis and breakdown of collagen and glycosaminoglycans, modulates metalloproteinases, promotes angiogenesis, and accelerates wound healing through multiple biological pathways.
View on PubMedThe Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health
Pickart L, Vasquez-Soltero JM, Margolina A
Reviewed GHK-Cu's role in preventing oxidative stress and age-related degeneration, demonstrating potent antioxidant, anti-inflammatory, and neuroprotective properties with implications for cognitive health and neurodegenerative disease prevention.
View on PubMedPreformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide
Ugwu SO, Blanchard J, Bhardwaj R, Dorr RT, Levine N, Hadley ME
Early pharmaceutical study characterizing Melanotan-II stability and formulation properties for potential use as a skin cancer chemopreventive agent through melanin-mediated photoprotection.
View on PubMedSkin pigmentation and pharmacokinetics of melanotan-I in humans
Dorr RT, Lines R, Levine N, et al.
First human pharmacokinetic study of melanocortin analogs demonstrating dose-dependent skin pigmentation increases, establishing the melanocortin receptor activation pathway for tanning without UV exposure.
View on PubMedEffect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles
Barnetson RS, Ooi TK, Zhuang L, et al.
Studied melanocortin analog effects on melanin synthesis in individuals with MC1R variants (fair-skinned phenotype), showing increased eumelanin production even in genetically UV-sensitive skin types.
View on PubMedRisks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review
Nelson ME, Bryant SM, Aks SE
Comprehensive safety review documenting risks of unregulated melanocortin analog use including nausea, flushing, changes in pigmented lesions, and potential complications from unmonitored self-administration.
View on PubMedThe Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Nadeeshani H, Li J, Ying T, Zhang B, Lu J
Updated review of NMN clinical trials showing supplementation increases blood NAD+ concentrations safely with oral dosing up to 900mg daily, with optimal clinical efficacy at 600mg for improving physical performance and NAD+ levels.
View on PubMedThe efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Yi L, Maier AB, Tao R, et al.
Rigorous multicenter RCT in 108 healthy middle-aged adults demonstrating NMN supplementation significantly increases blood NAD+ concentrations in a dose-dependent manner with good safety and tolerability profiles.
View on PubMedLong-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice
Mills KF, Yoshida S, Stein LR, et al.
Landmark study showing long-term NMN administration in mice suppressed age-related weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity, and ameliorated eye function without obvious toxicity.
View on PubMedChronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men
Igarashi M, Nakagawa-Nagahama Y, Miura M, et al.
Demonstrated that oral NMN supplementation in healthy older men significantly elevated blood NAD+ and NAD+ metabolite concentrations with nominally significant improvements in gait speed and grip test performance.
View on PubMedDesigning Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review
Lorenzen N, Nielsen SB
Comprehensive review of peptide stability challenges in aqueous solutions including chemical degradation, physical aggregation, and formulation strategies to enhance shelf life of reconstituted peptide therapeutics.
View on PubMedFactors affecting the physical stability (aggregation) of peptide therapeutics
Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE
Detailed analysis of factors affecting peptide stability and aggregation in therapeutic formulations, covering temperature, pH, concentration, and preservative effects critical for proper peptide reconstitution and storage.
View on PubMedAntimicrobial Preservatives for Protein and Peptide Formulations: An Overview
Ruiz-Rubio L, et al.
Overview of antimicrobial preservatives used in peptide formulations, including benzyl alcohol (the preservative in bacteriostatic water), their mechanisms of action, and their effects on peptide stability and integrity.
View on PubMedEmerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Various authors
2025 review documenting the expanding therapeutic applications of GLP-1 receptor agonists beyond diabetes and obesity, including liver disease, cardiovascular protection, neurodegenerative conditions, and substance use disorders.
View on PubMedThe expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
Various authors
Narrative review covering third-generation multi-agonists (tirzepatide, retatrutide, survodutide) targeting complementary incretin receptors with unprecedented metabolic efficacy, representing a paradigm shift in obesity and metabolic disease management.
View on PubMedResearch Disclaimer: The studies listed in this database are sourced from PubMed and peer-reviewed scientific journals. Summaries are provided for educational purposes only and should not be interpreted as medical advice. Many studies are preclinical (animal models) and may not translate directly to humans. Always consult with a qualified healthcare professional before making any health decisions based on research findings. Peptides are intended for research purposes only.